Oral Chinese herbal medicine in reducing the recurrence of colorectal adenoma after polypectomy: A protocol for the systematic review and meta-analysis

PLoS One. 2023 Oct 20;18(10):e0293244. doi: 10.1371/journal.pone.0293244. eCollection 2023.

Abstract

Background: Colorectal adenoma (CRA) is a significant precancerous lesion of sporadic colorectal cancer (CRC). CRA is likely to recur after polypectomy, increasing the risk of CRC. Chinese herbal medicine (CHM) has been used to reduce CRA recurrence. This review aims to evaluate the effectiveness and safety of oral CHM in reducing CRA recurrence compared to other treatments (placebo, routine care, no treatment, and conventional medicine).

Methods: We will search for randomised controlled trials (RCTs) from nine major biomedical databases in English and Chinese from their inception to July 2023. The RCTs that investigate the effects of oral CHM in reducing CRA recurrence compared to other treatments will be involved. We will exclude trials using CHM extract or external application of CHM, cohort study and cross-section study. The Cochrane Risk of Bias Tool version 2 will be used to assess the quality of included studies. Data will be analysed using Review Manager software 5.4 and STATA. The random effect model will be used. The heterogeneity of intervention effects will be tested by Chi2 (Cochrane Q) and I2 statistics. Funnel plots will assess publication bias if more than ten studies are included. Subgroup and sensitivity analysis will be conducted when possible.

Discussion: This review will discuss the effectiveness and safety of oral CHM in reducing CRA recurrence. It will show the critical information for clinicians in the decision-making process and countries to develop clinical guidelines on CRA management. Systematic review registration PROSPERO CRD42023324197.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drugs, Chinese Herbal* / therapeutic use
  • Humans
  • Medicine*
  • Meta-Analysis as Topic
  • Systematic Reviews as Topic

Substances

  • Drugs, Chinese Herbal

Grants and funding

This work is supported by RMIT PhD scholarship, China-Australia International Research Centre for Chinese Medicine, RMIT University. It is also supported by Special support for clinical research from the Guangzhou Science and Technology Plan Project, Guangzhou Key Laboratory for the Prevention and Treatment of Colorectal Inflammation - Cancer Transforming Diseases by Integrated Traditional Chinese and Western Medicine (grant number 202201020377); and State Key Laboratory of Wet Syndrome of Traditional Chinese Medicine, co-established by Guangdong Provincial and Ministry of China, research on Artificial Intelligence Image Acquisition and Recognition of Tongue Coating (grant number SZ2021ZZ2701/B67016 and B67017). The funders had no role in the study’s design or the writing of this protocol. The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.